豨莶通栓丸联合依达拉奉治疗缺血性脑卒中的效果

Effect of Xixian Tongshuan Pills combined with Edaravone in the treatment of ischemic stroke

目的探讨豨莶通栓丸联合依达拉奉治疗缺血性脑卒中的临床效果。方法选取2017年3月—2018年12月在北京市和平里医院就诊的98例缺血性脑卒中患者为研究对象,根据随机数字表法将其分为对照组(49例)和研究组(49例),对照组予以依达拉奉治疗,研究组予以豨莶通栓丸联合依达拉奉治疗。比较两组临床疗效、炎症因子指标[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]、量表评分[改良Barthel指数(BI)、美国国立卫生研究院卒中量表(NIHSS)]及脑血流指标(血浆黏度、血细胞比容、纤维蛋白原),记录两组治疗期间不良反应情况。结果研究组的临床总有效率高于对照组(P<0.05)。两组治疗后IL-6、TNF-α、hs-CRP水平均低于治疗前,且研究组低于对照组(P<0.05)。两组治疗后血浆黏度、血细胞比容、纤维蛋白原水平均低于治疗前,且研究组低于对照组(P<0.05)。两组治疗后BI评分高于治疗前,NIHSS评分低于治疗前(P<0.05),且研究组BI评分高于对照组,NIHSS评分低于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论豨莶通栓丸联合依达拉奉治疗缺血性脑卒中的效果确切,可有效改善炎症因子、脑血流指标,且用药安全性较好,具有一定的临床应用价值。

Objective To explore clinical effect of Xixian Tongshuan Pills combined with Edaravone in the treatment of ischemic stroke.Methods Ninety-eight patients with ischemic stroke admitted to Beijing Hepingli Hospital from March 2017 to December 2018 were selected as research objects,they were divided into control group(49 cases)and study group(49 cases)according to the random number table.Control group was treated with Edaravone,and study group was treated with Xixian Tongshuan Pills and Edaravone.Clinical efficacy,inflammatory factor indexes[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high sensitivity C-reactive protein(hs-CRP)],scale scores[improved Barthel index(BI),National Institutes of Health stroke scale(NIHSS)]and cerebral blood flow indexes(plasma viscosity,hematocrit,fibrinogen)were compared between two groups.The adverse reactions of two groups during the treatment were recorded.Results Total clinical effective rate of study group was higher than that of control group(P<0.05).The levels of IL-6,TNF-αand hs-CRP in two groups after treatment were lower than those before treatment,and those in study group were lower than those in control group(P<0.05).The plasma viscosity,hematocrit and fibrinogen of two groups after treatment were lower than those before treatment,and those in study group were lower than those in control group(P<0.05).BI score of two groups after treatment was higher than that before treatment,and NIHSS score of two groups was lower than that before treatment(P<0.05),and BI score of study group was higher than that of control group,and NIHSS score of study group was lower than that of control group(P<0.05).There was no difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion The effect of Xixian Tongshuan Pills combined with Edaravone in the treatment of ischemic stroke is definite.It can effectively improve inflammatory factors and cerebral blood flow indexes,and has good safety,which has certain clinical application value.